keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic agents

keyword
https://www.readbyqxmd.com/read/28103856/relationship-between-the-presence-of-baccalaureate-educated-rns-and-quality-of-care-a-cross-sectional-study-in-dutch-long-term-care-facilities
#1
Ramona Backhaus, Erik van Rossum, Hilde Verbeek, Ruud J G Halfens, Frans E S Tan, Elizabeth Capezuti, Jan P H Hamers
BACKGROUND: Recent evidence suggests that an increase in baccalaureate-educated registered nurses (BRNs) leads to better quality of care in hospitals. For geriatric long-term care facilities such as nursing homes, this relationship is less clear. Most studies assessing the relationship between nurse staffing and quality of care in long-term care facilities are US-based, and only a few have focused on the unique contribution of registered nurses. In this study, we focus on BRNs, as they are expected to serve as role models and change agents, while little is known about their unique contribution to quality of care in long-term care facilities...
January 19, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28101323/gabapentin-treatment-in-clozapine-induced-restless-legs-syndrome-two-cases-and-a-review-of-the-literature
#2
REVIEW
Vijaya Kumar, Ganesan Venkatasubramanian
Restless legs syndrome (RLS) is a neuro-sensorimotor disorder affecting 2-4% of adults. It is characterized by intense urges to move the legs, associated with unpleasant sensory disturbances in the legs occurring at rest and manifests mostly in the evening and night, relieved by movement. Diagnosis is primarily based on clinical presentation and the consensus criteria for the diagnosis have been established. Antipsychotics, the dopamine antagonists, have been reported to induce RLS. Dopamine agonists, the effective first-line treatment of RLS, carry the risk of inducing or worsening psychosis...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28072646/clozapine-treatment-of-olanzapine-induced-tardive-dyskinesia-a-case-report
#3
Dinesh Sangroula, Inderpreet Virk, Wali Mohammad, David A Kahn
Tardive dyskinesias (TD) are serious, often irreversible side effects of dopamine blocking agents, most commonly first-generation antipsychotics. No definitive treatment exists, with different interventions showing inconsistent results. We report a case of TD presenting after 12 years of olanzapine therapy in a 66-year-old Hispanic male with paranoid schizophrenia. The TD symptoms were successfully treated within a few weeks by switching to clozapine. Two cases of olanzapine-induced TD treated with clozapine have previously been reported, but in those cases, the symptom onset was quicker, ranging from a few months to a few years after initiation of olanzapine therapy, and the treatment response was relatively slower...
January 2017: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/28067751/efficacy-of-clozapine-on-dopamine-supersensitivity-psychosis-in-schizophrenia
#4
Yusuke Nakata, Nobuhisa Kanahara, Hiroshi Kimura, Hiroyuki Watanabe, Masaomi Iyo
Although the effectiveness of clozapine (CLZ) for patients with treatment-resistant schizophrenia (TRS) has been well established, its active mechanism has not been completely clarified. Several clinical studies showed that neuroleptic-induced dopamine supersensitivity psychosis (DSP) could be involved in the etiology of TRS. We preliminarily explored the possible beneficial effect of CLZ for dopamine supersensitivity schizophrenia. The present study is a case series. We followed 15 patients with DSP for about 2...
January 6, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28066110/assessment-of-impact-of-pharmacophilia-and-pharmacophobia-on-medication-adherence-in-patients-with-psychiatric-disorders-a-cross-sectional-study
#5
Mini Johnson Christudas, Balaji Sathyanarayana Gupta, Krishna Undela, Noel M Isaac, Dushad Ram, Madhan Ramesh
AIMS: To investigate the impact of pharmacophilia and pharmacophobia on medication adherence among patients with psychiatric disorders. MATERIALS AND METHODS: A cross-sectional, observational study was conducted in the Department of Psychiatry over a period of 2 months. Patients above 18 years of age with a psychiatric diagnosis as per the International Classification of Diseases 10 and receiving at least one psychotropic medication (any medication capable of affecting the mind, emotions, and behavior) for >1 month were enrolled in the study...
November 2016: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/28055066/association-between-antipsychotic-agents-and-risk-of-acute-respiratory-failure-in-patients-with-chronic-obstructive-pulmonary-disease
#6
Meng-Ting Wang, Chen-Liang Tsai, Chen Wei Lin, Chin-Bin Yeh, Yun-Han Wang, Hui-Lan Lin
Importance: Acute respiratory failure (ARF) is a life-threatening event that has been linked in case reports to antipsychotic use, but this association lacks population-based evidence. Particular attention should be focused on patients with chronic obstructive pulmonary disease (COPD) regarding this drug safety concern because these patients are prone to ARF and are commonly treated with antipsychotics. Objective: To determine whether the use of antipsychotics is associated with an increased risk of ARF in patients with COPD...
January 4, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28049911/concise-protecting-group-free-synthesis-of-nemonapride-via-eu-otf-3-catalyzed-aminolysis-of-3-4-epoxy-alcohol
#7
Shun-Ichiro Uesugi, Yusuke Sasano, Shogo Matsui, Naoki Kanoh, Yoshiharu Iwabuchi
A concise, protecting-group-free synthesis of the antipsychotic agent (+)-nemonapride has been achieved featuring a europium(III) trifluoromethanesulfonate (Eu(OTf)3)-catalyzed C4 selective aminolysis of a 3,4-epoxy alcohol by benzylamine and an expedient use of the resulting 4-benzylamino-1,3-diol product for constructing the pyrrolidine skeleton.
2017: Chemical & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28044943/forgotten-but-not-gone-new-developments-in-the-understanding-and-treatment-of-tardive-dyskinesia
#8
Jonathan M Meyer
The broad use of atypical antipsychotics was expected to dramatically reduce the prevalence and incidence of tardive dyskinesia (TD), but data show that TD remains an important challenge due the persistent nature of its symptoms and resistance to numerous treatment modalities, including antipsychotic discontinuation. Recent insights on genetic risk factors and new concepts surrounding pathophysiology have spurred interest in the possibility of targeted treatment for TD. As will be reviewed in this article, the number of evidence-based strategies for TD treatment is small: only clonazepam, amantadine, ginkgo biloba extract, and the vesicular monoamine transporter 2 (VMAT2) inhibitor tetrabenazine have compelling data...
December 2016: CNS Spectrums
https://www.readbyqxmd.com/read/28044942/emerging-pharmacological-therapies-in-schizophrenia-what-s-new-what-s-different-what-s-next
#9
Leslie Citrome
There are several new and emerging medication interventions for both the acute and maintenance treatment phases of schizophrenia. Recently approved are 2 new dopamine receptor partial agonists, brexpiprazole and cariprazine, as well as 2 new long-acting injectable antipsychotic formulations, aripiprazole lauroxil and 3-month paliperidone palmitate. Although differences in efficacy compared to other available choices are not expected, the new oral options offer different tolerability profiles that may be attractive for individual patients who have had difficulties with older medications...
December 2016: CNS Spectrums
https://www.readbyqxmd.com/read/28038920/analysis-of-differential-gene-expression-mediated-by-clozapine-in-human-postmortem-brains
#10
Brian J Lee, Luigi Marchionni, Carrie E Andrews, Alexis L Norris, Leslie G Nucifora, Yeewen Candace Wu, Robert A Wright, Jonathan Pevsner, Christopher A Ross, Russell L Margolis, Akira Sawa, Frederick C Nucifora
Clozapine is the only medication indicated for treating refractory schizophrenia, due to its superior efficacy among all antipsychotic agents, but its mechanism of action is poorly understood. To date, no studies of human postmortem brain have characterized the gene expression response to clozapine. Therefore, we addressed this question by analyzing expression data extracted from published microarray studies involving brains of patients on antipsychotic therapy. We first performed a systematic review and identified four microarray studies of postmortem brains from antipsychotic-treated patients, then extracted the expression data...
December 27, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/28025106/effect-of-lysosomotropic-molecules-on-cellular-homeostasis
#11
REVIEW
Omer F Kuzu, Mesut Toprak, M Anwar Noory, Gavin P Robertson
Weak bases that readily penetrate through the lipid bilayer and accumulate inside the acidic organelles are known as lysosomotropic molecules. Many lysosomotropic compounds exhibit therapeutic activity and are commonly used as antidepressant, antipsychotic, antihistamine, or antimalarial agents. Interestingly, studies also have shown increased sensitivity of cancer cells to certain lysosomotropic agents and suggested their mechanism of action as a promising approach for selective destruction of cancer cells...
December 23, 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28019033/evidence-for-the-herg-liability-of-antihistamines-antipsychotics-and-anti-infective-agents-a-systematic-literature-review-from-the-aritmo-project
#12
REVIEW
Lorna Hazell, Emanuel Raschi, Fabrizio De Ponti, Simon H L Thomas, Francesco Salvo, Ernst Ahlberg Helgee, Scott Boyer, Miriam Sturkenboom, Saad Shakir
A systematic review was performed to categorize the hERG (human ether-a-go-go-related gene) liability of antihistamines, antipsychotics, and anti-infectives and to compare it with current clinical risk of torsade de pointes (TdP). Eligible studies were hERG assays reporting half-minimal inhibitory concentrations (IC50). A "hERG safety margin" was calculated from the IC50 divided by the peak human plasma concentration (free Cmax ). A margin below 30 defined hERG liability. Each drug was assigned an "uncertainty score" based on volume, consistency, precision, and internal and external validity of evidence...
December 26, 2016: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28017279/cardiovascular-remodeling-and-the-peripheral-serotonergic-system
#13
REVIEW
Estelle Ayme-Dietrich, Gaëlle Aubertin-Kirch, Luc Maroteaux, Laurent Monassier
Plasma 5-hydroxytryptamine (5-HT; serotonin), released from blood platelets, plays a major role in the human cardiovascular system. Besides the effect of endogenous serotonin, many drugs targeting serotonergic receptors are widely used in the general population (antiobesity agents, antidepressants, antipsychotics, antimigraine agents), and may enhance the cardiovascular risk. Depending on the type of serotonin receptor activated and its location, the use of these compounds triggers acute and chronic effects...
December 21, 2016: Archives of Cardiovascular Diseases
https://www.readbyqxmd.com/read/28008259/efficacy-and-tolerability-of-topiramate-augmentation-therapy-for-schizophrenia-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#14
Yuji Okuyama, Kazuto Oya, Shinji Matsunaga, Taro Kishi, Nakao Iwata
This study aimed to perform a comprehensive meta-analysis of topiramate-augmentation therapy in patients with schizophrenia receiving antipsychotic agents. Data published up to June 20, 2016 were obtained from the PubMed, PsycINFO, and Cochrane Library databases. Twelve randomized controlled trials comparing topiramate to placebo or antipsychotic only were included (n=676 patients). The primary outcome was change in overall symptoms. Relative risk (RR) and standardized mean difference (SMD), along with 95% confidence intervals, were calculated using random effects model for each outcome...
2016: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28004588/2015-annual-report-of-the-american-association-of-poison-control-centers-national-poison-data-system-npds-33rd-annual-report
#15
James B Mowry, Daniel A Spyker, Daniel E Brooks, Ashlea Zimmerman, Jay L Schauben
INTRODUCTION: This is the 33rd Annual Report of the American Association of Poison Control Centers' (AAPCC) National Poison Data System (NPDS). As of 1 January 2015, 55 of the nation's poison centers (PCs) uploaded case data automatically to NPDS. The upload interval was 9.52 [7.40, 13.6] (median [25%, 75%]) minutes, creating a near real-time national exposure and information database and surveillance system. METHODS: We analyzed the case data tabulating specific indices from NPDS...
December 2016: Clinical Toxicology
https://www.readbyqxmd.com/read/28002167/haloperidol-versus-ondansetron-for-treatment-of-established-nausea-and-vomiting-following-general-anesthesia-a-randomized-clinical-trial
#16
Vanda G Yazbeck-Karam, Sahar M Siddik-Sayyid, Hanane B Barakat, Serge Korjian, Marie T Aouad
BACKGROUND: Haloperidol is an antipsychotic. At low doses, it is a useful agent for the prophylaxis of postoperative nausea and vomiting (PONV). However, its use for treating established PONV has not been well studied. METHODS: This randomized double-blinded trial tested whether haloperidol is noninferior to ondansetron for the early treatment of established PONV in adult patients undergoing general anesthesia. The primary outcome is whether patients were PONV free during the first 4 hours...
February 2017: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/28001043/biological-insights-of-the-dopaminergic-stabilizer-acr16-at-the-binding-pocket-of-dopamine-d2-receptor
#17
Ramin Ekhteiari Salmas, Philip Seeman, Busecan Aksoydan, Matthias Stein, Mine Yurtsever, Serdar Durdagi
The dopamine D2 receptor (D2R) plays an important part in the human central nervous system and is considered to be a focal target of antipsychotic agents. It is structurally modeled in active and inactive states, in which homo-dimerization reaction of the D2R monomers is also applied. The ASP2314 (also known as ACR16) ligand, a D2R stabilizer, is used in tests to evaluate how dimerization and conformational changes may alter the ligand binding space and to provide information on alterations in inhibitory mechanisms upon activation...
December 21, 2016: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/27997108/in-vivo-systems-response-profiling-and-multivariate-classification-of-cns-active-compounds-a-structured-tool-for-cns-drug-discovery
#18
Susanna Waters, Peder Svensson, Johan Kullingsjö, Henrik Ponten, Theresa Andreasson, Ylva Sunesson, Elisabeth Ljung, Clas Sonesson, Nicholas Waters
This paper describes the application of in vivo systems response profiling in CNS drug discovery by a process referred to as the Integrative Screening Process. The biological response profile, treated as an array, is used as major outcome for selection of candidate drugs. Dose-response data, including ex vivo brain monoaminergic biomarkers, and behavioural descriptors, are systematically collected, and analysed by PCA and PLS, yielding multivariate characterisation across compounds. The approach is exemplified by assessing a new class of CNS active compounds, the dopidines, compared to other monoamine modulating compounds including antipsychotics, antidepressants, and procognitive agents...
December 20, 2016: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/27986997/risk-of-parkinsonism-induced-by-flunarizine-or-cinnarizine-a-population-based-study
#19
Hsiu-Li Lin, Hsiu-Chen Lin, Yuan-Fu Tseng, Shih-Chang Chen, Chien-Yeh Hsu
PURPOSE: This retrospective cohort study used a population-based dataset to test the risk for parkinsonism in patients receiving flunarizine and cinnarizine, compared with matched controls. METHODS: Data were obtained from the National Health Insurance Research Dataset of Taiwan. Patients receiving flunarizine or cinnarizine for more than 1 month between 2000 and 2005 were enrolled. Exclusion criteria included receiving flunarizine, cinnarizine, or antipsychotics for more than 1 month during 1997-1999, a history of neurodegenerative diseases, and an age of less than 30 years...
December 16, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27983772/metabolic-response-to-olanzapine-in-healthy-chinese-subjects-with-rs7093146-polymorphism-in-transcription-factor-7-like-2-gene-tcf7l2-a-prospective-study
#20
Qing Li, Dong Guo, Hong Yang, Zhi Ye, Jin Huang, Yan Shu
Olanzapine is a widely used atypical antipsychotic with significant weight gain and other metabolic side effects. The locus of the transcription factor 7-like 2 (TCF7L2) gene is strongly associated with type 2 diabetes (T2D). The goal of this study was to determine whether polymorphic TCF7L2 is involved in the susceptibility to the metabolic changes associated with the atypical antipsychotic agents (AAPs). In this study, a parallel clinical study with 3-day consecutive administration of olanzapine (10 mg/day) was conducted in 17 healthy subjects with a genotype of TCF7L2 rs7903146 CC (N=10) or CT (N=7)...
December 16, 2016: Basic & Clinical Pharmacology & Toxicology
keyword
keyword
43995
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"